Publisher： Adis International
ISSN： 0114-9954
Source： Reactions Weekly, Vol.1, Iss.1276, 2009-01, pp. : 3-3
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Ipilimumab: will benefits outweigh risks in the eyes of the FDA?
Reactions Weekly, Vol. 1, Iss. 1307, 2010-01 ,pp. :
Access to resources
Recommend
Risks and benefits of perioperative -blockers
Reactions Weekly, Vol. 1, Iss. 1203, 2008-01 ,pp. :
Risks and benefits of allergen immunotherapy
By Rogala Barbara Glück Joanna
Expert Opinion on Drug Safety, Vol. 8, Iss. 3, 2009-05 ,pp. :
Expert Opinion on Drug Safety, Vol. 4, Iss. 6, 2005-11 ,pp. :